NeoImmuneTech (XKRX:950220) Marketable Securities : ₩333.38 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NeoImmuneTech Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. NeoImmuneTech's Marketable Securities for the quarter that ended in Dec. 2023 was ₩333.38 Mil.

NeoImmuneTech's annual Marketable Securities increased from Dec. 2021 (₩220.29 Mil) to Dec. 2022 (₩1,444.63 Mil) but then declined from Dec. 2022 (₩1,444.63 Mil) to Dec. 2023 (₩333.38 Mil).

NeoImmuneTech Marketable Securities Historical Data

The historical data trend for NeoImmuneTech's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoImmuneTech Marketable Securities Chart

NeoImmuneTech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

5,890.18

0.90

220.29

1,444.63

333.38

NeoImmuneTech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Marketable Securities	Get a 7-Day Free Trial											1,444.63	1,509.92	1,298.79	1,147.86	333.38

NeoImmuneTech Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

NeoImmuneTech (XKRX:950220) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

NeoImmuneTech Marketable Securities Related Terms

Thank you for viewing the detailed overview of NeoImmuneTech's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoImmuneTech (XKRX:950220) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

2400 Research Boulevard, Suite 250, Rockville, MD, USA, 20850

Website

http://www.neoimmunetech.com

NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.

NeoImmuneTech (XKRX:950220) Headlines

No Headlines